Everest Medicines (HKG:1952) said the first patient was dosed in a clinical trial of its mRNA cancer vaccine EVM16 at Peking University Cancer Hospital,
The study aims to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EVM16 as a monotherapy and in combination with a PD-1 antibody in advanced or recurrent solid tumors.
The clinical trial of EVM16 is being conducted jointly at Peking University Cancer Hospital and Fudan University Shanghai Cancer Center, according to a Thursday news release.
Shares of the biopharmaceutical company soared 18% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.